Cytosorbents Corp (NASDAQ:CTSO) CFO Kathleen P. Bloch sold 11,176 shares of the business’s stock in a transaction that occurred on Thursday, March 15th. The stock was sold at an average price of $8.25, for a total value of $92,202.00. Following the transaction, the chief financial officer now directly owns 261,246 shares in the company, valued at $2,155,279.50. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.
Shares of Cytosorbents stock traded down $0.18 on Monday, hitting $7.72. The company’s stock had a trading volume of 74,162 shares, compared to its average volume of 185,584. Cytosorbents Corp has a one year low of $3.30 and a one year high of $8.25. The firm has a market cap of $232.82, a price-to-earnings ratio of -27.68 and a beta of -0.17. The company has a debt-to-equity ratio of 0.58, a quick ratio of 2.54 and a current ratio of 2.64.
Cytosorbents (NASDAQ:CTSO) last announced its earnings results on Thursday, March 8th. The medical research company reported ($0.12) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.10) by ($0.02). Cytosorbents had a negative net margin of 52.08% and a negative return on equity of 118.07%. The business had revenue of $4.65 million during the quarter, compared to analyst estimates of $4.56 million. analysts anticipate that Cytosorbents Corp will post -0.46 earnings per share for the current year.
Institutional investors and hedge funds have recently made changes to their positions in the business. Skylands Capital LLC increased its holdings in shares of Cytosorbents by 45.1% in the 4th quarter. Skylands Capital LLC now owns 725,608 shares of the medical research company’s stock valued at $4,716,000 after acquiring an additional 225,558 shares during the last quarter. Wealthcare Advisory Partners LLC bought a new stake in shares of Cytosorbents in the 3rd quarter valued at approximately $365,000. Fortaleza Asset Management Inc. increased its holdings in shares of Cytosorbents by 60.9% in the 4th quarter. Fortaleza Asset Management Inc. now owns 37,615 shares of the medical research company’s stock valued at $244,000 after acquiring an additional 14,240 shares during the last quarter. B. Riley Financial Inc. bought a new stake in shares of Cytosorbents in the 4th quarter valued at approximately $992,000. Finally, BlueCrest Capital Management Ltd bought a new stake in shares of Cytosorbents in the 4th quarter valued at approximately $396,000. 10.84% of the stock is currently owned by institutional investors.
A number of brokerages have issued reports on CTSO. Cowen set a $9.00 target price on Cytosorbents and gave the company a “buy” rating in a research report on Thursday, March 8th. Maxim Group set a $12.00 target price on Cytosorbents and gave the company a “buy” rating in a research report on Friday, March 9th. ValuEngine raised Cytosorbents from a “sell” rating to a “hold” rating in a research report on Tuesday, January 9th. HC Wainwright set a $14.00 target price on Cytosorbents and gave the company a “buy” rating in a research report on Friday, March 9th. Finally, B. Riley set a $11.00 target price on Cytosorbents and gave the company a “buy” rating in a research report on Friday, December 22nd. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $11.05.
TRADEMARK VIOLATION WARNING: This piece of content was originally posted by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this piece of content on another website, it was copied illegally and republished in violation of international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.thelincolnianonline.com/2018/03/19/insider-selling-cytosorbents-corp-ctso-cfo-sells-11176-shares-of-stock.html.
CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.
Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.